Contact IMV

IMV Executive Assistant


tel. (612) 624-1926

fax. (612) 625-1108


18-242 Moos Tower
515 Delaware St. SE
Minneapolis, MN 55455

General Questions:

Christine Clouser
Assistant Professor



Phone: (612) 624-5172



B.S. Chemistry, St. Cloud State University

M.S. Biological Chemistry, University of Michigan

Ph.D. Biological Chemistry, University of Michigan

Postdoctoral Fellow, Univesity of Minnesota

Research Interests

HIV lethal mutagenesis; HIV quasispecies

The high mutation rate of HIV allows for the development of drug resistance and the ability of the virus to escape immune detection. However, many mutations produced during the error-prone replication are detrimental to the virus and lead to the production of non-infectious virus. The error rate of HIV-1 is high enough to ensure enough diversity for the virus to replicate under adverse conditions such as the presence of antiviral compounds or immune surveillance, yet low enough that the virus does not accumulate enough mutations to render the virus non-infectious. It has been predicted that increasing the mutation rate above a certain threshold, known as the error threshold, would extinguish viral infectivity. As a result, drugs that increase the mutation frequency of HIV-1 past the error threshold may be a viable antiretroviral therapy. To test this, I am investigating the effects of two FDA-approved drugs (decitabine and gemcitabine) on their ability to eliminate HIV infectivity by elevating the HIV mutation rate.  These studies represent a collaboration with Louis Mansky and Steven Patterson.  Presently, I am extending my studies into mouse model and working on methods to deliver these drugs in a pill form. I am interested in the clinical translation of this novel combination therapy.

My graduate work at the University of Michigan focused on post-translational processing and trafficking of the Luteinizing Hormone Receptor, a GPCR critical for reproduction. While in Michigan, both course and volunteer work sparked my interest in virology with a specific focus on HIV.

In my free time, I enjoy outdoor activities and am an avid reader. 

Selected Recent Publications

  • Clouser, CL, Bonnac, L, Mansky, LM, Patterson, SE. 2013. Characterization of permeability, stability, and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs. Antiviral Chemistry & Chemotherapy. Epub ahead of print.
  • Clouser, CL, Chauhan, J, Bess, MA, Oploo, JL, Zhou, D, Dimick-Gray, S, Mansky, LM, Patterson, SE. 2012. Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg Med Chem Lett. 22:6642-6646.
  • Clouser CL, Holtz CM, Mullet M, Crankshaw DL, Briggs JE, O’Sullivan MG, Patterson SE, Mansky LM. 2012.  Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1. Antimicrobial Agents and Chemotherapy. 56:1942-1948.
  • Greggs, WM 3rd, Clouser CL, Patterson SE, Mansky LM. 2012. Discovery of drugs that possess activity against feline leukemia virus. Journal of General Virology 93:900-905.
  • Greggs WM 3rd, Clouser CL, Patterson SE, Mansky LM. 2011. Broadening the use of antiretroviral therapy: the case for feline leukemia virus. Therapeutics and Clinical Risk Management. 7:115-22.
  • Greggs, W.M., Clouser, C.L., Patterson, S.E., and L.M. Mansky. 2011. Broadening the use of antiretroviral therapy: the case for feline leukemia virus. Therapeutics and Clinical Risk Management Epub ahead of print.
  • Clouser, C.L., Holtz, C.M., Mullet, M., Crankshaw, D.L., Briggs, J.E., Chauhan, J., VanHoutan, I.M., Patterson, S.E., and L.M. Mansky. 2010. Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine. PLoS One 6:e15840.
  • Ni, Z., Knorr, D.A., Clouser, C.L., Hexum, M.K., Southern, P., Mansky, L.M., Park, I.-H., and D.S. Kaufman. 2010. Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity utilizing diverse cellular mechanisms. Journal of Virology 85:43-50.
  • Clouser, C.L., Patterson, S.E., and L.M. Mansky. 2010. Exploiting drug repositioning for the discovery of a novel HIV combination therapy. Journal of Virology 84:9301-9309.
  • Dapp, M.D., Clouser, C.L., Patterson, S.E. and L.M. Mansky. 2009. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. Journal of Virology 83:11950-58.

My Research in the News

Mansky and Clouser

Featured News & Events

'Wisc-e-sota', a Joint UMN-UW Virology Training Grant Symposium was first held on Friday, Sepbember 20th, 2013 at the Uniiversity of Wisconsin-La Crosse, Cartwright Center. This was the inaugural collaborative symposium of the NIH T32-supported virology training programs at the University of Wisconsin-Madison and the University of Minnesota-Twin Cities. Talks and poster sessions were presented by students, postdocs and faculty. The second UMN-UW Virology Training Grant Symposium will be held in the Fall 2014. Details to follow.

The 2014 IMV Symposium will be held on May 12, 2014 and Mark Denison (Vanderbilt) and Bert Semler (UC-Irvine) will be the Keynote Speakers. Click on the link below to register and submit abstracts.

About the IMV icon

Read about bacteriophage phi 29 and why it matters.

IMV Timeline

Explore nearly a century's worth of discovery in the field of virology at the University of Minnesota.


"This Week in Virology" from professor Vincent Racaniello.